Please re-tweet:
We are hiring! Assistant Professor in statistical genetics. Also, hiring a postdoc. Reach out to hear more. Also, if you’ll be at #ASHG24#ASHG2024, we could meet. https://t.co/OLHRllzBQl
@NancyGenetics receiving the leadershipaward #ASHG2023 - a lighthouse for humble supportive leadership, mentorship & science that has truly fostered a generation - I owe you so much Nancy - we all do - congratulations - you deserve this so very much #iaminaweofyou ♥️🍀✨
@arbelharpak @CellGenomics@be_stranger @sexchrlab It's an important and insightful piece of work! We were lucky to see it right in time to include in our recommendations published in @CellPressNews https://t.co/budaGvNkAL
🙏🏼 I express my deepest gratitude to Isabel Goldman, Sarah Geisler, and Julie Ho Sung from Cell Press for their invaluable guidance and unwavering support. Your expertise has been instrumental in this important endeavor. 🤝 #CellPressNews
Today, @WHOSTP is announcing an historic slate of bold actions across government and business, civic, academic, nonprofit, community-based, and philanthropic organizations to advance the Biden-Harris Administration’s STEMM equity and excellence priorities. https://t.co/i0gGTSFrF9
Our study highlights the utility of using biobank-scale phenotypic and sequencing data to improve our understanding of how APOECh influences the risk of AD, lipid phenotypes, and beyond.
Excited to share that our characterization of APOE Christchurch carriers in 455,306 UK Biobank participants is out on medRxiv. Feedback is welcome! https://t.co/HDtf8qdxRA
Through our evaluations of clinical diagnosis, self-reported and prescription medications, biomarker measurements, and polygenic risk scores, we found that APOECh carriers have lower levels of apolipoprotein B and have lower polygenic risk score-based AD risk.
It is time for me to hand the baton on - but it has been a truly fantastic experience being at the helm and I strongly encourage future leaders to apply as this is a great position. Please apply and feel free to reach out to me privately with questions. 2/2